RVNC

Revance Therapeutics, Inc.

4.09 USD
+0.28 (+7.35%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Revance Therapeutics, Inc. stock is up 46.07% since 30 days ago. The next earnings date is Aug 6, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 27.27% of the previous 10 July’s closed higher than June. In the last 1 Unusual Options Trades, there were 1 PUT.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
10 Jul 15:35 17 Jan, 2025 2.50 PUT 490 1247

About Revance Therapeutics, Inc.

Revance Therapeutics, Inc. engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia.